论文部分内容阅读
可溶性血管内皮生长因子受体1(sFlt1)是血管内皮生长因子受体1的剪接变体,sFlt-1能阻断血管内皮生长因子和胎盘生长因子的生物学效应,因而造成全身内皮功能失调,产生高血压、蛋白尿等临床表现。子痫前期发病前5周循环中sFlt1水平就有显著升高,子痫前期患者体内高水平的sFlt1可作为预测指标。拮抗sFlt1药物在子痫前期及子痫治疗中的价值值得进一步探讨。
Soluble vascular endothelial growth factor receptor 1 (sFlt1) is a splicing variant of vascular endothelial growth factor receptor 1, sFlt-1 can block the biological effects of vascular endothelial growth factor and placental growth factor, resulting in systemic endothelial dysfunction, Produce high blood pressure, proteinuria and other clinical manifestations. SFlt1 levels in the 5 weeks before the onset of preeclampsia were significantly increased, high levels of sFlt1 in patients with preeclampsia can be used as a predictor. Antagonistic sFlt1 drugs in the treatment of preeclampsia and eclampsia worth further exploration.